Chantal Veillon-Berteloot, Executive Vice President and Chief Human Resources Officer of Integra LifeSciences Holdings Corp, filed a Form 4 on September 4, 2026, reporting a disposition of common stock on September 1, 2026.

Key Highlights

  • Reporting person: Chantal Veillon-Berteloot, EVP and CHRO of Integra LifeSciences Holdings Corp (NASDAQ:IART)
  • Transaction: 1,455 shares of common stock disposed of (transaction code F) on September 1, 2026
  • Price per share: $16.62
  • Remaining ownership: 20,772 shares of common stock held directly following the transaction
  • Filing date: September 4, 2026, signed by Lesha Shinn as Attorney-in-Fact

Integra LifeSciences CHRO Reports Share Disposition Under Code F

According to the filing, Chantal Veillon-Berteloot, who serves as Executive Vice President and Chief Human Resources Officer at Integra LifeSciences Holdings Corp, reported a single transaction in Table I of the Form 4. On September 1, 2026, she disposed of 1,455 shares of common stock at a price of $16.62 per share. The transaction is recorded under transaction code F, which typically denotes shares withheld by the issuer for tax purposes upon the vesting of equity awards.

Following the reported transaction, the filing discloses that Veillon-Berteloot directly holds 20,772 shares of Integra LifeSciences common stock. No derivative securities transactions were reported in Table II of the filing. The Form 4 was filed by one reporting person and covers the date of earliest transaction as September 1, 2026.

The filing was signed on September 4, 2026, by Lesha Shinn as Attorney-in-Fact for Chantal Veillon-Berteloot. No amendment date was indicated, and the filing does not reference any Rule 10b5-1(c) trading plan in connection with this transaction.

What Was Disclosed

The Form 4 discloses a disposition of 1,455 shares of Integra LifeSciences common stock at $16.62 per share by the company's EVP and CHRO on September 1, 2026, leaving her with a direct beneficial ownership of 20,772 shares.